No ProtrusionNCT07154004

The Sponsor Assigns Test Products to Six Skin Areas According to a Concealed Randomization Schedule; Neither the Evaluating Physicians Nor the Participants Know Which Product is Applied to Which Site, Preventing Bias.

A study testing Test Serum 897222 210, Test Serum 897222 212 and Test Serum 897250 39 in people with No Protrusion and No Open Wound, run by BEIJING YUANBEN INFORMATION CONSULTING CO., LTD at 1 site in China.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

This is a single-center, double-blind, randomized, and controlled study. The sponsor keeps the allocation of products to the six test sites confidential. Neither the evaluating physicians nor the participants know which product is applied to which site. Read more about this study

Who is it for?: Ages 18 to 65 years, women onlyHealthy volunteers can take part
Conditions the study is for: No Protrusion, No Open Wound, No Severe Allergic Reaction
What is being tested?: Test Serum 897222 210, Test Serum 897222 212 and Test Serum 897250 39
Could I receive a placebo?: No, everyone receives an active treatment
How many people: 30 participants
Where: 1 siteChina
Study dates: 21 Dec 2024to 31 May 2025
Phase: Interventional
Are there results?: None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 to 65 years
Women only
Healthy volunteers accepted
Adult, Older adult

Who may be able to join

1) Chinese physically healthy female participants, aged between 18 and 65 years old; 2) All skin types (including dry, normal, oily, and combination); 3) Have no significant skin defects, scars, tattoos, protrusions, open wounds, or other factors that would affect the evaluation on the inner side of the forearm skin; 4) Have no severe allergic reactions to the testing reagents containing dansyl chloride; 5) Agree to avoid swimming, prolonged sun exposure, sauna, and steam baths during the study period; 6) Agree to discontinue the use of any other cleansing and skincare products on the forearm during the study period; 7) Willingness to read, write and sign an informed consent form to demonstrate willingness and ability to participate; 8) Willingness to comply with all requirements of the research protocol; 9) Have no reason assessed by the investigators as unsuitable for participation in the testing; 10) Intends to complete the study and is willing and able to follow all study instructions.
11) Subjects who could comply with standards during the whole study that refrain from the use of towel, bath ball or any other bath sponges on the forearm.

Who cannot join

1) Undergoing dermatological treatment or those who have taken whitening or anti-aging dietary supplements within the past month; 2) Have allergies to skincare products, soap, alcohol, fragrances, or medications; 3) Have used antihistamines within the past week or immunosuppressants within the past month; 4) Have applied any anti-inflammatory drugs to the test area within the past two months; 5) Have skin conditions such as psoriasis, eczema, dermatitis, skin cancer, etc.; 6) Insulin-dependent diabetes patients; 7) Undergoing treatment for asthma or other chronic respiratory diseases; 8) Have received cancer chemotherapy within the past 6 months; 9) With immunodeficiency or autoimmune diseases; 10) Breastfeeding or pregnant women; 11) Have undergone bilateral mastectomy and bilateral axillary lymph node dissection; 12) With facial erythema, follicular papules, sunspots, wounds, abrasions, tattoos, acne, or any other conditions that may affect the evaluation of test results; 13) With high sensitivity; 14) Have participated in intense outdoor activities or travel that may cause skin damage due to sun exposure within the month prior to the test; 15) Concurrently participating in another clinical trial or who have participated in a facial clinical trial within the past three months; 16) Have applied vitamin A analogues, alpha-hydroxy acids, salicylic acid, hydroquinone, or prescription drugs (antibiotics, vitamin A analogues, alpha-hydroxy acids, and corticosteroids) within the past six months, or oral contraceptives (continuation is allowed if the same contraceptive has been used consistently for the past six months); 17) PI or experts who believe that there are other medical reasons that may affect the test results.

Trial locations and contacts

1 site in 1 country.

China1 site

Beijing Yuanben Information Consulting Co., Ltd
Beijing

Other trials in China

About this study

Official title: Clinical Study on Epidermal Cell Renewal Efficacy of 5 Products

The investigator will recruit 33 Chinese female participants and aim to complete the study with at least 30 of them. Each participant will be followed for 23 consecutive days.

Day 0: After signing informed consent and passing screening, a staff member performs a dansyl chloride patch test. The reagent is placed in a Finn chamber, applied to the inner forearm, and sealed with waterproof tape.
Day 1 (≥20 h later): Participants return to the site. The patches are removed, photographs are taken, and the designated test products are applied to the marked areas.
Days 2-21: Participants visit daily for product application by staff. After each use they report any adverse reactions, specifying symptoms, severity, location, and duration. Starting on Day 1, a dermatologist performs daily clinical scoring and photography of the test areas.

Throughout the study, participants must avoid sunscreen and any other skin-care products on the inner forearms. From Day 0 to Day 1 they may not bathe or wet the forearms; during the remaining application period they may shower but must not rub or scrub the inner forearms, and must still refrain from any other topical products.

Conditions: No Protrusion, No Open Wound, No Severe Allergic Reaction, No Scar, No Tattoo, No Significant Skin Defect
Being tested: Test Serum 897222 210, Test Serum 897222 212, Test Serum 897250 39, Test Serum 897250 102D, Test Serum 774569 67

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Test Serum 897222 210Other
Repeated application
Test Serum 897222 212Other
Repeated application
Test Serum 897250 39Other
Repeated application
Test Serum 897250 102DOther
Repeated application
Test Serum 774569 67Other
Repeated application

Study groups in NCT07154004
Study group	Role	What they receive
Group 1	Experimental	Not described Receives: Other: Test Serum 897222 210; Other: Test Serum 897222 212; Other: Test Serum 897250 39; Other: Test Serum 897250 102D; Other: Test Serum 774569 67

What is being measured

The primary outcome is the main question the study is designed to answer.

Clinical Grading by Dermatologist
A dermatologist should use a UV lamp to illuminate the inner side of the forearm and evaluate the fluorescence area in the target region daily from Day 1 to Day 22
Measured: Day 1 to Day 22

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

21 Dec 202431 May 2025

First posted4 Sep 2025
Study start21 Dec 2024
Primary completion31 May 2025
Study completion31 May 2025

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Other trials for No ProtrusionStudies of the same condition, open and under way.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase N/A
Primary purpose: Other
Allocation: Not applicable
Intervention model: Single group
Masking: None (open label)
Enrolment: 30 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT07154004
Sponsor's protocol ID: UB24CL09012
Status last verified: Aug 2025
First submitted: 21 Aug 2025
Last updated: 4 Sep 2025
Results posted: No
Data monitoring committee: No
FDA-regulated drug: No
FDA-regulated device: No
Individual data sharing: No

Study at a glance

From the registry record, last updated by the sponsor on 4 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: Clinical Study on Epidermal Cell Renewal Efficacy of 5 Products
ClinicalTrials.gov ID: NCT07154004
Acronym / sponsor ID: UB24CL09012
Conditions: No Protrusion, No Open Wound, No Severe Allergic Reaction, No Scar, No Tattoo, No Significant Skin Defect
Study type: Interventional
Recruitment status: Completed
Enrolment: 30 participants (actual)
Lead sponsor: BEIJING YUANBEN INFORMATION CONSULTING CO., LTDIndustry (pharma, biotech, devices)
Study start: 21 Dec 2024 (actual)
Primary completion: 31 May 2025 (actual)
Study completion: 31 May 2025 (actual)
First posted: 4 Sep 2025 (actual)
Results: Not posted in the source record

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

The investigator will recruit 33 Chinese female participants and aim to complete the study with at least 30 of them. Each participant will be followed for 23 consecutive days.

Day 0: After signing informed consent and passing screening, a staff member performs a dansyl chloride patch test. The reagent is placed in a Finn chamber, applied to the inner forearm, and sealed with waterproof tape.
Day 1 (≥20 h later): Participants return to the site. The patches are removed, photographs are taken, and the designated test products are applied to the marked areas.
Days 2-21: Participants visit daily for product application by staff. After each use they report any adverse reactions, specifying symptoms, severity, location, and duration. Starting on Day 1, a dermatologist performs daily clinical scoring and photography of the test areas.

Study design

Primary purpose: Other
Allocation: Not applicable
Intervention model: Single group
Masking: None (open label)
Number of arms: 1

Arm	Type	Receives
Group 1	Experimental	Other: Test Serum 897222 210, Other: Test Serum 897222 212, Other: Test Serum 897250 39, Other: Test Serum 897250 102D, Other: Test Serum 774569 67

Who may qualify

Ages: 18 to 65 years
Sex: Female only
Healthy volunteers: Accepted
Age groups: Adult, Older adult

Key inclusion criteria (2 listed)

1) Chinese physically healthy female participants, aged between 18 and 65 years old; 2) All skin types (including dry, normal, oily, and combination); 3) Have no significant skin defects, scars, tattoos, protrusions, open wounds, or other factors that would affect the evaluation on the inner side of the forearm skin; 4) Have no severe allergic reactions to the testing reagents containing dansyl chloride; 5) Agree to avoid swimming, prolonged sun exposure, sauna, and steam baths during the study period; 6) Agree to discontinue the use of any other cleansing and skincare products on the forearm during the study period; 7) Willingness to read, write and sign an informed consent form to demonstrate willingness and ability to participate; 8) Willingness to comply with all requirements of the research protocol; 9) Have no reason assessed by the investigators as unsuitable for participation in the testing; 10) Intends to complete the study and is willing and able to follow all study instructions.
11) Subjects who could comply with standards during the whole study that refrain from the use of towel, bath ball or any other bath sponges on the forearm.

Key exclusion criteria (1 listed)

1) Undergoing dermatological treatment or those who have taken whitening or anti-aging dietary supplements within the past month; 2) Have allergies to skincare products, soap, alcohol, fragrances, or medications; 3) Have used antihistamines within the past week or immunosuppressants within the past month; 4) Have applied any anti-inflammatory drugs to the test area within the past two months; 5) Have skin conditions such as psoriasis, eczema, dermatitis, skin cancer, etc.; 6) Insulin-dependent diabetes patients; 7) Undergoing treatment for asthma or other chronic respiratory diseases; 8) Have received cancer chemotherapy within the past 6 months; 9) With immunodeficiency or autoimmune diseases; 10) Breastfeeding or pregnant women; 11) Have undergone bilateral mastectomy and bilateral axillary lymph node dissection; 12) With facial erythema, follicular papules, sunspots, wounds, abrasions, tattoos, acne, or any other conditions that may affect the evaluation of test results; 13) With high sensitivity; 14) Have participated in intense outdoor activities or travel that may cause skin damage due to sun exposure within the month prior to the test; 15) Concurrently participating in another clinical trial or who have participated in a facial clinical trial within the past three months; 16) Have applied vitamin A analogues, alpha-hydroxy acids, salicylic acid, hydroquinone, or prescription drugs (antibiotics, vitamin A analogues, alpha-hydroxy acids, and corticosteroids) within the past six months, or oral contraceptives (continuation is allowed if the same contraceptive has been used consistently for the past six months); 17) PI or experts who believe that there are other medical reasons that may affect the test results.

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
Test Serum 897222 210Repeated application	Other	Group 1
Test Serum 897222 212Repeated application	Other	Group 1
Test Serum 897250 39Repeated application	Other	Group 1
Test Serum 897250 102DRepeated application	Other	Group 1
Test Serum 774569 67Repeated application	Other	Group 1

Primary outcome

Clinical Grading by Dermatologist
Time frame: Day 1 to Day 22
A dermatologist should use a UV lamp to illuminate the inner side of the forearm and evaluate the fluorescence area in the target region daily from Day 1 to Day 22

Results and safety

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 4 Sep 2025.
Individual participant dataSharing planned: No

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

The record lists no contact. Use the official record to reach the sponsor.

1 site in 1 country: see every site and its status.

Questions about this trial

What is this clinical trial studying?

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 4 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Clinical Grading by Dermatologist (time frame: Day 1 to Day 22). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07154004.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Sep 2025.